Volume Alert - PFE 30.44 Pfizer Inc $PFE Hit a hig
Post# of 190
Posted On: 11/12/2014 11:19:49 AM
Volume Alert - PFE 30.44 Pfizer Inc $PFE Hit a high today of 30.54 Closing the day 10:30 at 30.44 +0.12 +0.40% With a day low of 30.23 and a total volume of 4,515,516.
PFE Recent Posts: http://investorshangout.com/Pfizer-PFE-52267/
PFE Pfizer Inc Recent Headline News
Early Glance: Pharmaceuticals companies
AP - 13 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.54 (-0.37), BAX: 70.73 (-0.03), PFE: 30.37 (+0.05), BMY: 58.49 (-0.23)
Today's Market: Mergers, Rumors And Earnings Moving These Stocks
Matthew Smith - at Seeking Alpha - 14 mins ago
ZTS: 43.29 (-0.43), T: 35.35 (+0.25), VRX: 130.37 (+0.34), FOSL: 112.47 (+8.72), BBT: 37.34 (-0.99), PFE: 30.37 (+0.05), KORS: 69.65 (+0.76), SUSQ: 13.08 (+3.18)
Bill Ackman's Latest Target: Zoetis Inc.
Todd Campbell, The Motley Fool - Motley Fool - 38 mins ago
Source: Zoetis. Pershing Square's Bill Ackman is probably best known for his relentless advocacy regarding his short position in Herbalife , but he's also captured a lot of attention this year as being a key voice of support for the sale of ...
ZTS: 43.29 (-0.43), AGN: 196.68 (+1.34), HLF: 37.32 (-0.23), VRX: 130.37 (+0.34), PFE: 30.37 (+0.05), MRK: 59.27 (-0.10), LLY: 67.52 (-0.33)
5 Things Actavis plc's Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - 1 hr 58 mins ago
The pharmaceutical industry has had a banner year in many ways, fueled by a slew of major drug approvals in recent years, numerous mergers and acquisitions, and significant corporate reorganizations that have helped to boost earnings. The specialty...
DRTX: 24.00 (unch), AGN: 196.68 (+1.34), ACT: 241.54 (-2.09), IRWD: 13.66 (-0.24), CBST: 71.26 (-0.16), PFE: 30.37 (+0.05)
Warren Buffett's Investing Strategy: Is Pfizer Inc. a Perfect Fit?
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 12, 7:03AM CST
Here at The Motley Fool, we sing the praises of Warren Buffett quite often -- and with good reason. Buffett, in a hair over 60 years, turned a small fortune of around $10,000 into a net worth of more than $70 billion as of this past Friday. Clearly,...
PFE: 30.37 (+0.05)
Pfizer Highlights Leadership in Rheumatology and Inflammation with Data to be Presented at the ACR/ARHP 2014 Annual Meeting
Business Wire - Wed Nov 12, 7:01AM CST
--Efficacy Results from a Phase 2 Study of Anti-IL-6 in Patients with Systemic Lupus Erythematosus
PFE: 30.37 (+0.05)
Most active New York Stock Exchange-traded stocks
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
ZTS: 43.29 (-0.43), GE: 26.42 (+0.04), F: 14.53 (+0.16), ABX.TO: 13.27 (+0.06), ABX: 11.73 (+0.09), S: 4.93 (+0.04), PFE: 30.37 (+0.05), BAC: 17.12 (-0.20), TWTR: 39.85 (+0.26), GNW: 8.62 (+0.22), VZ: 50.93 (+0.32), JNPR: 20.62 (+0.34)
Final Glance: Pharmaceuticals companies
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.54 (-0.37), BAX: 70.73 (-0.03), PFE: 30.37 (+0.05), BMY: 58.49 (-0.23)
Amgen's brodalumab beats Stelara in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:52PM CST
CANF: 2.44 (-0.21), JNJ: 108.54 (-0.37), IDRA: 2.48 (-0.10), DERM: 16.04 (+0.01), MRK: 59.27 (-0.10), PFE: 30.37 (+0.05), AZN: 74.13 (-0.07), AMGN: 161.45 (-0.97), GSK: 45.67 (-0.29), HSP: 57.87 (+0.56), NVS: 92.77 (unch), CELG: 107.17 (-0.68)
Zoetis shares jump on investment by activist
By The Associated Press - AP - Tue Nov 11, 3:44PM CST
Zoetis Inc. shares jumped Tuesday on a report that activist investor William Ackman has taken a stake in the animal health company and could push for its sale.
ZTS: 43.28 (-0.44), PFE: 30.37 (+0.05)
Dow Index Dogs: 10% Bonus In 5 Lowest-Price, High-Yield Stocks
Fredrik Arnold - at Seeking Alpha - Tue Nov 11, 1:26PM CST
KO: 42.66 (+0.15), T: 35.35 (+0.25), GE: 26.42 (+0.04), PFE: 30.37 (+0.05), MRK: 59.27 (-0.10), MCD: 95.13 (-0.01), PG: 89.70 (+0.03), CVX: 117.77 (-0.67), VZ: 50.93 (+0.32), CSCO: 25.06 (-0.09)
Re-Examining My Bullish Thesis On Walgreen
Alexander J. Poulos - at Seeking Alpha - Tue Nov 11, 1:04PM CST
SHPG: 200.80 (-1.41), PFE: 30.37 (+0.05), AZN: 74.13 (-0.07), ABBV: 63.71 (-0.14), WAG: 66.99 (-0.51)
Midday Glance: Pharmaceuticals companies
AP - Tue Nov 11, 12:52PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.54 (-0.37), BAX: 70.73 (-0.03), PFE: 30.37 (+0.05), BMY: 58.49 (-0.23)
Marketing And R&D, Again
Derek Lowe - at Seeking Alpha - Tue Nov 11, 11:39AM CST
The BBC has an article posted with the title "Pharmaceutical Industry Gets High on Fat Profits", so at least you know where that one's going. And it reads just as you'd expect- if you haven't had enough pharma-bashing recently, that'll...
PFE: 30.37 (+0.05)
Pfizer Does Not Need AstraZeneca
Vin Colby - at Seeking Alpha - Tue Nov 11, 11:34AM CST
PFE: 30.37 (+0.05)
Can Arena Pharmaceuticals Inc. Overcome Belviq's Slow Launch?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 10:15AM CST
The new generation of diet pills approved by the Food and Drug Administration have stumbled out of the gate. Specifically, Arena Pharmaceuticals ' Belviq and VIVUS 's Qsymia reported a combined 283,000 prescriptions in the third quarter, with...
PFE: 30.37 (+0.05), VVUS: 3.25 (-0.02), GSK: 45.67 (-0.29), ARNA: 4.55 (+0.06)
Global Hospital Pharmaceuticals Market Outlook 2020: AstraZeneca, Bayer, Eli Lilly and Co, GSK, J&J, Merck Pfizer & Sanofi-Aventis Dominate the $10 Billion Market
M2 - Tue Nov 11, 9:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/g45smv/hospital) has announced the addition of the "Hospital Pharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global hospital pharmaceuticals market was valued at USD 2.65 billion in 2013 and is estimated to reach USD 10.90 billion in 2020, declining with a CAGR of (11.5)% from 2014 to 2020 The oncology segment accounts for the largest market share in 2013 wherein the immunomodulating agent holds the maximum share among other drug class commonly prescribed in hospital settings. Followed by oncology, cardiovascular disease account for the second largest share in which anti-cholinergic agent has the fastest declining growth rate. Decline in anti-cholinergic agent is primarily due to exclusivity loss of several high selling drugs such as VESIcare and Enablex which will lose their patent rights in 2015 and 2018 respectively. Geographically, North America region constitutes the largest market for global hospital pharmaceuticals market in 2013; however, Asia-Pacific is predicted to foresee the highest growth rate during the forecast period from 2014 to 2020. This growth has been attributed to large population base and increasing incidences of cardiovascular diseases and cancer incidences in both of the emerging regions. Moreover, according to the Central Bureau of Health Intelligence, the number of government hospitals in India increased from 4,571 in 2000 to 11,993 in 2011. Rising number of hospitals and growing awareness about branded drugs for treating chronic disease conditions is fueling the demand for hospital pharmaceuticals in these regions. Additionally, significant growth in medical tourism in Asia Pacific, Africa, the Middle East and Latin America would boost the hospital pharmaceuticals market. The leading market players in this market include AstraZeneca plc, Bayer AG, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi -Aventis. Scope of the Report Cardiology - Anti-Adrenergic Drugs - Calcium Channel Blockers - Diuretic Drugs - Anti-Arrhythmic Drugs - Others Oncology - Alkylating Agents - Anti-Metabolites - Hormonal Agents - Immunomodulating Agents - Miscellaneous Drugs Nephrology and Urology - Diuretic Agents - Anti-Hypertensive Agents - Phosphate Binders - Anticholinergic Drugs - 5-Alpha Reductase Inhibitors Neurology - Anti-Anxiety Agents - Detail2Anti-Migraine Drugs - Antidepressant Drugs - Anti-Psychotic Drugs Pain - Anticonvulsant Drugs - Anesthetic Drugs - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Opioids - Non-Narcotics Analgesic Drugs Infection - Antibacterial Drugs - Antiviral Drugs - Antifungal Drugs - Antiparasite Drugs Global Hospital Pharmaceuticals Market, by Major Indications Cardiology - Coronary Heart Diseases - Stroke - High Blood Pressure - Heart Failure - Others Oncology - Lung Cancer - Breast Cancer - Colorectal Cancer - Prostate Cancer - Others Nephrology and Urology - Acute Kidney Failure - Chronic Kidney Diseases - Glomerular Diseases - Diabetes - Others Neurology - Epilepsy - Alzheimer;s Disease - Parkinson;s Disease - Multiple Sclerosis - Others Pain - Neuropathic Pain - Fibromyalgia - Osteoarthritis - Rheumatoid Arthritis - Cancer Pain Infection - Detail1Tuberculosis - Pneumonia - Hepatitis A - Hepatitis B - Candida Infection - Fungal Meningitis - Shigellosis - Amoebiasis - Other For more information visit http://www.researchandmarkets.com/research/g45smv/hospital
JNJ: 108.54 (-0.37), PFE: 30.37 (+0.05), MRK: 59.27 (-0.10), AZN: 74.13 (-0.07), LLY: 67.52 (-0.33), GSK: 45.67 (-0.29)
Insider Trading Recap for AK Steel, Pfizer, Chesapeake Energy, Plug Power, Twitter, and RF Micro Devices
PR Newswire - Tue Nov 11, 7:45AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: AK Steel (NYSE:AKS), Pfizer (NYSE
FE), Chesapeake Energy (NYSE:CHK), Plug Power (NASDAQ LUG), Twitter (NYSE:TWTR), and RF Micro Devices (NASDAQ:RFMD).
PLUG: 4.26 (-0.82), CHK: 23.27 (-0.16), PFE: 30.37 (+0.05), AKS: 6.34 (+0.02), TWTR: 39.85 (+0.26), RFMD: 13.24 (-0.11)
PFE Recent Posts: http://investorshangout.com/Pfizer-PFE-52267/
PFE Pfizer Inc Recent Headline News
Early Glance: Pharmaceuticals companies
AP - 13 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.54 (-0.37), BAX: 70.73 (-0.03), PFE: 30.37 (+0.05), BMY: 58.49 (-0.23)
Today's Market: Mergers, Rumors And Earnings Moving These Stocks
Matthew Smith - at Seeking Alpha - 14 mins ago
ZTS: 43.29 (-0.43), T: 35.35 (+0.25), VRX: 130.37 (+0.34), FOSL: 112.47 (+8.72), BBT: 37.34 (-0.99), PFE: 30.37 (+0.05), KORS: 69.65 (+0.76), SUSQ: 13.08 (+3.18)
Bill Ackman's Latest Target: Zoetis Inc.
Todd Campbell, The Motley Fool - Motley Fool - 38 mins ago
Source: Zoetis. Pershing Square's Bill Ackman is probably best known for his relentless advocacy regarding his short position in Herbalife , but he's also captured a lot of attention this year as being a key voice of support for the sale of ...
ZTS: 43.29 (-0.43), AGN: 196.68 (+1.34), HLF: 37.32 (-0.23), VRX: 130.37 (+0.34), PFE: 30.37 (+0.05), MRK: 59.27 (-0.10), LLY: 67.52 (-0.33)
5 Things Actavis plc's Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - 1 hr 58 mins ago
The pharmaceutical industry has had a banner year in many ways, fueled by a slew of major drug approvals in recent years, numerous mergers and acquisitions, and significant corporate reorganizations that have helped to boost earnings. The specialty...
DRTX: 24.00 (unch), AGN: 196.68 (+1.34), ACT: 241.54 (-2.09), IRWD: 13.66 (-0.24), CBST: 71.26 (-0.16), PFE: 30.37 (+0.05)
Warren Buffett's Investing Strategy: Is Pfizer Inc. a Perfect Fit?
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 12, 7:03AM CST
Here at The Motley Fool, we sing the praises of Warren Buffett quite often -- and with good reason. Buffett, in a hair over 60 years, turned a small fortune of around $10,000 into a net worth of more than $70 billion as of this past Friday. Clearly,...
PFE: 30.37 (+0.05)
Pfizer Highlights Leadership in Rheumatology and Inflammation with Data to be Presented at the ACR/ARHP 2014 Annual Meeting
Business Wire - Wed Nov 12, 7:01AM CST
--Efficacy Results from a Phase 2 Study of Anti-IL-6 in Patients with Systemic Lupus Erythematosus
PFE: 30.37 (+0.05)
Most active New York Stock Exchange-traded stocks
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
ZTS: 43.29 (-0.43), GE: 26.42 (+0.04), F: 14.53 (+0.16), ABX.TO: 13.27 (+0.06), ABX: 11.73 (+0.09), S: 4.93 (+0.04), PFE: 30.37 (+0.05), BAC: 17.12 (-0.20), TWTR: 39.85 (+0.26), GNW: 8.62 (+0.22), VZ: 50.93 (+0.32), JNPR: 20.62 (+0.34)
Final Glance: Pharmaceuticals companies
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.54 (-0.37), BAX: 70.73 (-0.03), PFE: 30.37 (+0.05), BMY: 58.49 (-0.23)
Amgen's brodalumab beats Stelara in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:52PM CST
CANF: 2.44 (-0.21), JNJ: 108.54 (-0.37), IDRA: 2.48 (-0.10), DERM: 16.04 (+0.01), MRK: 59.27 (-0.10), PFE: 30.37 (+0.05), AZN: 74.13 (-0.07), AMGN: 161.45 (-0.97), GSK: 45.67 (-0.29), HSP: 57.87 (+0.56), NVS: 92.77 (unch), CELG: 107.17 (-0.68)
Zoetis shares jump on investment by activist
By The Associated Press - AP - Tue Nov 11, 3:44PM CST
Zoetis Inc. shares jumped Tuesday on a report that activist investor William Ackman has taken a stake in the animal health company and could push for its sale.
ZTS: 43.28 (-0.44), PFE: 30.37 (+0.05)
Dow Index Dogs: 10% Bonus In 5 Lowest-Price, High-Yield Stocks
Fredrik Arnold - at Seeking Alpha - Tue Nov 11, 1:26PM CST
KO: 42.66 (+0.15), T: 35.35 (+0.25), GE: 26.42 (+0.04), PFE: 30.37 (+0.05), MRK: 59.27 (-0.10), MCD: 95.13 (-0.01), PG: 89.70 (+0.03), CVX: 117.77 (-0.67), VZ: 50.93 (+0.32), CSCO: 25.06 (-0.09)
Re-Examining My Bullish Thesis On Walgreen
Alexander J. Poulos - at Seeking Alpha - Tue Nov 11, 1:04PM CST
SHPG: 200.80 (-1.41), PFE: 30.37 (+0.05), AZN: 74.13 (-0.07), ABBV: 63.71 (-0.14), WAG: 66.99 (-0.51)
Midday Glance: Pharmaceuticals companies
AP - Tue Nov 11, 12:52PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.54 (-0.37), BAX: 70.73 (-0.03), PFE: 30.37 (+0.05), BMY: 58.49 (-0.23)
Marketing And R&D, Again
Derek Lowe - at Seeking Alpha - Tue Nov 11, 11:39AM CST
The BBC has an article posted with the title "Pharmaceutical Industry Gets High on Fat Profits", so at least you know where that one's going. And it reads just as you'd expect- if you haven't had enough pharma-bashing recently, that'll...
PFE: 30.37 (+0.05)
Pfizer Does Not Need AstraZeneca
Vin Colby - at Seeking Alpha - Tue Nov 11, 11:34AM CST
PFE: 30.37 (+0.05)
Can Arena Pharmaceuticals Inc. Overcome Belviq's Slow Launch?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 10:15AM CST
The new generation of diet pills approved by the Food and Drug Administration have stumbled out of the gate. Specifically, Arena Pharmaceuticals ' Belviq and VIVUS 's Qsymia reported a combined 283,000 prescriptions in the third quarter, with...
PFE: 30.37 (+0.05), VVUS: 3.25 (-0.02), GSK: 45.67 (-0.29), ARNA: 4.55 (+0.06)
Global Hospital Pharmaceuticals Market Outlook 2020: AstraZeneca, Bayer, Eli Lilly and Co, GSK, J&J, Merck Pfizer & Sanofi-Aventis Dominate the $10 Billion Market
M2 - Tue Nov 11, 9:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/g45smv/hospital) has announced the addition of the "Hospital Pharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global hospital pharmaceuticals market was valued at USD 2.65 billion in 2013 and is estimated to reach USD 10.90 billion in 2020, declining with a CAGR of (11.5)% from 2014 to 2020 The oncology segment accounts for the largest market share in 2013 wherein the immunomodulating agent holds the maximum share among other drug class commonly prescribed in hospital settings. Followed by oncology, cardiovascular disease account for the second largest share in which anti-cholinergic agent has the fastest declining growth rate. Decline in anti-cholinergic agent is primarily due to exclusivity loss of several high selling drugs such as VESIcare and Enablex which will lose their patent rights in 2015 and 2018 respectively. Geographically, North America region constitutes the largest market for global hospital pharmaceuticals market in 2013; however, Asia-Pacific is predicted to foresee the highest growth rate during the forecast period from 2014 to 2020. This growth has been attributed to large population base and increasing incidences of cardiovascular diseases and cancer incidences in both of the emerging regions. Moreover, according to the Central Bureau of Health Intelligence, the number of government hospitals in India increased from 4,571 in 2000 to 11,993 in 2011. Rising number of hospitals and growing awareness about branded drugs for treating chronic disease conditions is fueling the demand for hospital pharmaceuticals in these regions. Additionally, significant growth in medical tourism in Asia Pacific, Africa, the Middle East and Latin America would boost the hospital pharmaceuticals market. The leading market players in this market include AstraZeneca plc, Bayer AG, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi -Aventis. Scope of the Report Cardiology - Anti-Adrenergic Drugs - Calcium Channel Blockers - Diuretic Drugs - Anti-Arrhythmic Drugs - Others Oncology - Alkylating Agents - Anti-Metabolites - Hormonal Agents - Immunomodulating Agents - Miscellaneous Drugs Nephrology and Urology - Diuretic Agents - Anti-Hypertensive Agents - Phosphate Binders - Anticholinergic Drugs - 5-Alpha Reductase Inhibitors Neurology - Anti-Anxiety Agents - Detail2Anti-Migraine Drugs - Antidepressant Drugs - Anti-Psychotic Drugs Pain - Anticonvulsant Drugs - Anesthetic Drugs - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Opioids - Non-Narcotics Analgesic Drugs Infection - Antibacterial Drugs - Antiviral Drugs - Antifungal Drugs - Antiparasite Drugs Global Hospital Pharmaceuticals Market, by Major Indications Cardiology - Coronary Heart Diseases - Stroke - High Blood Pressure - Heart Failure - Others Oncology - Lung Cancer - Breast Cancer - Colorectal Cancer - Prostate Cancer - Others Nephrology and Urology - Acute Kidney Failure - Chronic Kidney Diseases - Glomerular Diseases - Diabetes - Others Neurology - Epilepsy - Alzheimer;s Disease - Parkinson;s Disease - Multiple Sclerosis - Others Pain - Neuropathic Pain - Fibromyalgia - Osteoarthritis - Rheumatoid Arthritis - Cancer Pain Infection - Detail1Tuberculosis - Pneumonia - Hepatitis A - Hepatitis B - Candida Infection - Fungal Meningitis - Shigellosis - Amoebiasis - Other For more information visit http://www.researchandmarkets.com/research/g45smv/hospital
JNJ: 108.54 (-0.37), PFE: 30.37 (+0.05), MRK: 59.27 (-0.10), AZN: 74.13 (-0.07), LLY: 67.52 (-0.33), GSK: 45.67 (-0.29)
Insider Trading Recap for AK Steel, Pfizer, Chesapeake Energy, Plug Power, Twitter, and RF Micro Devices
PR Newswire - Tue Nov 11, 7:45AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: AK Steel (NYSE:AKS), Pfizer (NYSE
FE), Chesapeake Energy (NYSE:CHK), Plug Power (NASDAQ LUG), Twitter (NYSE:TWTR), and RF Micro Devices (NASDAQ:RFMD). PLUG: 4.26 (-0.82), CHK: 23.27 (-0.16), PFE: 30.37 (+0.05), AKS: 6.34 (+0.02), TWTR: 39.85 (+0.26), RFMD: 13.24 (-0.11)
(0)
(0)Pfizer Inc. (PFE) Stock Research Links
Scroll down for more posts ▼